• Profile

A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial

HPB Feb 11, 2022

Via this multicenter phase II trial, researchers sought to ascertain the efficacy and safety of bevacizumab plus mFOLFOX6 for patients with advanced colorectal liver metastases (CRLMs) harboring mutant-type KRAS.

  • Researchers performed evaluation of surgical indication every 4 cycles of bevacizumab plus mFOLFOX6 among patients with advanced CRLMs (tumor number of ≥5 and/or technically unresectable) harboring mutant-type KRAS.

  • Among 29 registered patients from six centers, complete and partial responses were observed at the rates of 0% and 62.1%, respectively.

  • There were 19 and 1 patient who received R0 and R1 resections, respectively (R0 resection rate: 65.5%).

  • Overall findings suggest achievement of a high R0 resection rate for advanced CRLMs harboring mutant-type KRAS by using bevacizumab plus mFOLFOX6, resulting in favorable survival.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen